CS
BEAM icon

Comerica Securities’s Beam Therapeutics BEAM Stock Holding History

Comerica Securities’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10
Closed -$391 – 571
2022
Q4 		$391 Buy
+10
New +$448 ﹤0.01% 1438

Other funds holding BEAM

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Farallon Capital Management
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Comerica Securities's BEAM Position: Q1 2023 in Review

Comerica Securities sold out of Beam Therapeutics (BEAM) in Q1 2023, closing a stake of 10 shares — an estimated $391 sold.

Comerica Securities first reported a position in BEAM in Q4 2022 and held it in 1 quarter. The position peaked at $391 in Q4 2022. 206 funds tracked by Wall St. Rank hold BEAM as of Q1 2023.

  • Comerica Securities reported no remaining Beam Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Comerica Securities sold 10 Beam Therapeutics shares in Q1 2023, an estimated $391.
  • Comerica Securities first reported a position in Beam Therapeutics in Q4 2022 and held it in 1 quarter.
  • Comerica Securities's Beam Therapeutics position peaked at $391 in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2023.

Based on Comerica Securities's 13F filing for Q1 2023, filed 27 Apr 2023.